tepoxalin has been researched along with Osteogenic Sarcoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bushey, JJ; Cavatorta, D; Levine, CB; Loftus, JP; Sevier, CS; Wakshlag, JJ | 1 |
| Dow, SW; Gustafson, DL; Hansen, RJ; Sottnik, JL; Thamm, DH | 1 |
| Bushey, JJ; Goupil, RC; Peters-Kennedy, J; Wakshlag, JJ | 1 |
3 other study(ies) available for tepoxalin and Osteogenic Sarcoma
| Article | Year |
|---|---|
The 5-lipoxygenase inhibitor tepoxalin induces oxidative damage and altered PTEN status prior to apoptosis in canine osteosarcoma cell lines.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cyclooxygenase Inhibitors; Dog Diseases; Dogs; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Immunosuppressive Agents; Lipoxygenase Inhibitors; Osteosarcoma; Oxidative Stress; PTEN Phosphohydrolase; Pyrazoles | 2016 |
Induction of VEGF by tepoxalin does not lead to increased tumour growth in a canine osteosarcoma xenograft.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Western; Bone Neoplasms; Cell Proliferation; Dog Diseases; Dogs; Hypoxia-Inducible Factor 1, alpha Subunit; In Vitro Techniques; Male; Mice; Osteosarcoma; Pyrazoles; Transplantation, Heterologous; Tumor Burden; Vascular Endothelial Growth Factors | 2011 |
Prevalence of 5-lipoxygenase expression in canine osteosarcoma and the effects of a dual 5-lipoxygenase/cyclooxygenase inhibitor on osteosarcoma cells in vitro and in vivo.
Topics: Animals; Arachidonate 5-Lipoxygenase; Bone Neoplasms; Cell Proliferation; Cell Survival; Cyclooxygenase Inhibitors; Dog Diseases; Dogs; Female; Immunohistochemistry; Lipoxygenase Inhibitors; Male; Mice; Mice, Nude; Osteosarcoma; Pyrazoles; Retrospective Studies; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |